News
EXAS
103.18
+0.51%
0.52
Hims & Hers Is Offering a New Cancer Test. It May Not Be Ready for Prime Time.
Barron‘s · 2d ago
GENEOSCOPY: PTAB'S RULING CONFIRMS GENEOSCOPY'S LONG-HELD POSITION AND CLEARS PATH FOR CONTINUED COMMERCIALIZATION OF COLOSENSE
Reuters · 2d ago
Exact Sciences ticks higher amid reports HSR for Abbott deal expired
Seeking Alpha · 2d ago
Exact Sciences ‘applauds’ passage of MCED legislation
TipRanks · 5d ago
Oncotype DX Breast Recurrence Score® Test Surpasses 2 Million Patients Worldwide
Barchart · 5d ago
The Best Dividend King to Buy With $150
NASDAQ · 6d ago
Weekly Report: what happened at EXAS last week (0126-0130)?
Weekly Report · 6d ago
GERMAN CARTEL OFFICE: APPROVED PLANNED ACQUISITION OF EXACT SCIENCES CORPORATION BY ABBOTT LABORATORIES IN PRELIMINARY PROCEEDINGS
Reuters · 01/30 08:36
Alger Small Cap Focus Fund Q4 2025 Portfolio Update
Seeking Alpha · 01/29 18:22
Guardant Health: Look For Explosive Revenue Growth Ahead
Seeking Alpha · 01/26 14:31
Weekly Report: what happened at EXAS last week (0119-0123)?
Weekly Report · 01/26 09:46
Alger Small Cap Growth Fund Q4 2025 Portfolio Update
Seeking Alpha · 01/26 08:54
Abbott Laboratories Raised Prices, Prompting Sales Slump -- Update
Dow Jones · 01/22 18:21
Abbott says ‘making great progress’ towards closing Exact Sciences deal
TipRanks · 01/22 15:00
Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints
Benzinga · 01/22 14:48
Abbott Laboratories 4Q Sales Grow, Outlook Underwhelms
Dow Jones · 01/22 13:08
Abbott Q4 sales misses analyst expectations, hurt by diagnostics unit's challenges
Reuters · 01/22 12:40
Abbott still sees Exact Sciences acquisition closing in Q2
TipRanks · 01/22 12:40
Alger Mid Cap Focus Fund Q4 2025 Portfolio Update
Seeking Alpha · 01/22 10:15
Wednesday's ETF with Unusual Volume: FBT
NASDAQ · 01/21 18:34
More
Webull provides a variety of real-time EXAS stock news. You can receive the latest news about Exact Sciences Corp through multiple platforms. This information may help you make smarter investment decisions.
About EXAS
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. It is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.